Over the past six months, conversations with senior medical writing and regulatory leaders across large pharmaceutical organizations have begun to converge around a clear and consistent message. Despite the rapid rise of Generative AI, enthusiasm inside regulated environments is becoming more measured. What is emerging is not resistance to AI, but a more mature, risk-aware understanding of where different technologies genuinely belong. This shift closely mirrors the direction set out in the...